Qutenza

ApprovedSmall molecule

Astellas

Qutenza is one of 157 small molecule programs targeting Neuropathic Pain. It is currently in Approved.

Indications

Total Trials

Active Trials

156

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

Peripheral NeuropathyActive, not recruiting

AmputationActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

OsteoarthritisActive, not recruiting

Neuropathic PainApproved

Active, not recruiting

Peripheral NeuropathyPreclinical

Active, not recruiting

AmputationPreclinical

Active, not recruiting

Pulmonary Arterial HypertensionPhase 2

Active, not recruiting

OsteoarthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Qutenza

Astellas

Approved

1 2

Cataflam

Bayer Aspirin

Enbrel

2 5

Naproxen Sodium

Bayer

Preclinical

1 6

Ansaid

PPharmacia and Upjohn

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Benadryl

SGLT2 Inhibitor

1 10

Ozone

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Peripheral Neuropathy Due to Chemotherapy

NCT06744816

Clinical

Trials by Indication[1]

Neuropathic Pain3 trials

A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain

Completed· Astellas logo

Astellas··NCT02171182·319 enrolled

Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain

Completed·—·Phase 2·NCT03317613·84 enrolled

A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment

Completed· Astellas logo

Astellas·Phase 4·NCT01713426·568 enrolled

Treatment3 trials

A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients

Completed· Astellas logo

Astellas·Phase 3·NCT01478607·468 enrolled

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

Completed·UUniversity of Rochester·Phase 2·NCT01260454·6 enrolled

Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch

Completed· Astellas logo

Astellas·Phase 4·NCT01416116·122 enrolled

Arteriovenous Fistula1 trial

Qutenza (Topical Capsaicin 8%) for Painful Arteriovenous Fistulae

Unknown status·NNHS Greater Glasgow and Clyde··NCT01748422·20 enrolled

Pulmonary Arterial Hypertension1 trial

Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients

Completed·IImperial College London·Phase 2·NCT01393795·11 enrolled

Peripheral Neuropathy1 trial

Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)

Unknown status·—·N/A·NCT05560516·102 enrolled

6 more indications

Renal Failure1 trial

Qutenza for Critical Ischaemia in End Stage Renal Failure

Unknown status·EEmma Aitken·Phase 4·NCT01704339·20 enrolled

Osteoarthritis1 trial

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

Completed·CCentrexion Therapeutics·Phase 1·NCT03576508·16 enrolled

Amputation1 trial

Pre-emptive Analgesia With Qutenza in Lower Limb Amputation

Unknown status·NNHS Greater Glasgow and Clyde··NCT01748435·30 enrolled

Effectiveness1 trial

Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage

Completed· Astellas logo

Astellas·Phase 4·NCT01252160·306 enrolled

Age1 trial

Efficacity of a Standardized Hypnotic Message During the Application of a Qutenza (Capsaicin) 8% Patch

Completed·IInstitut de Cancérologie de Lorraine·Phase 3·NCT02822625·69 enrolled

Peripheral Neuropathy Due to Chemotherapy1 trial

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06744816·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Qutenza. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Qutenza compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Qutenza. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Astellas

Qutenza

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neuropathic Pain3 trials

Treatment3 trials

Arteriovenous Fistula1 trial

Pulmonary Arterial Hypertension1 trial

Peripheral Neuropathy1 trial

Renal Failure1 trial

Osteoarthritis1 trial

Amputation1 trial

Effectiveness1 trial

Age1 trial

Peripheral Neuropathy Due to Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News